Placeholder image


Addex Therapeutics is a clinical-stage pharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.

Addex’s lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2 clinical trial for the treatment of epilepsy.

The company’s second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in dyskinesia associated with Parkinson’s disease and post-stroke/TBI recovery.

Addex’s partnership with Indivior on GABAB PAM is advancing multiple drug candidates through clinical candidate selection for substance use disorder. Under the agreement with Indivior, Addex is advancing an independent GABAB PAM program for chronic cough through clinical candidate selection.

Addex also holds a 20% share in a private company, Neurosterix Pharma Sàrl (equivalent to an LLC) which is advancing a portfolio of allosteric modulator programs including M4 PAM for schizophrenia, mGlu7 NAM for stress related disorders and mGlu2 NAM for mild neurocognitive disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange.

Find out more about ouClinical and Pre-Clinical Pipeline.